RxDoctor Payments Data

David Colon, MD

Internal Medicine · Charlotte, NCNPI 1447406079

Payments from drug & device makers

$5,265in general payments, 2019–2025

Across 300 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$578
  • AbbVie$555
  • Novo Nordisk$535
  • AstraZeneca$471
  • Pfizer$394
  • GSK$290
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$5,250100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,265 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$134,521
Medicare patients
292
Services billed
3,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide122$142,295
JardianceEmpagliflozin47$57,944
EliquisApixaban46$44,899
JanuviaSitagliptin Phosphate25$39,159
MyrbetriqMirabegron49$29,483
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$27,411
LinzessLinaclotide33$25,463
FarxigaDapagliflozin Propanediol15$24,032
TradjentaLinagliptin29$23,710
ShingrixVaricella-Zoster Ge/As01b/Pf101$22,052
Repatha SureclickEvolocumab17$21,722
TrulicityDulaglutide20$21,504
XareltoRivaroxaban15$21,251
Breo ElliptaFluticasone/Vilanterol30$13,922
Tresiba Flextouch U-100Insulin Degludec25$12,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$535$142,295122 claims
Boehringer IngelheimJardiance, Tradjenta$207$81,65476 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta$290$75,268185 claims
PfizerEliquis$394$44,89946 claims
MerckJanuvia, Lagevrio (Eua)$143$42,35336 claims
Lilly USA, LLCTrulicity, Mounjaro$271$32,76931 claims
AbbVieLinzess, Synthroid$555$29,93677 claims
Astellas Pharma US IncMyrbetriq$17$29,48349 claims
AstraZenecaFarxiga$471$24,03215 claims
Johnson & JohnsonXarelto$251$21,25115 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$109$2,298245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →